In recent years, Robert Ripley has watched spiking drug prices menace his budget like a fast-rising flood.

The longtime chief of pharmacy for Trinity Health, a Catholic chain of 93 hospitals from New York to California, said he’s never seen anything like it in his 30-plus years in the business. The eye-popping prices of new branded drugs are one issue. But even worse are the wild price hikes and sudden shortages of generics that have been available for many decades.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Yeah, I already subscribe to the Globe, and this is an article in today’s paper. Why should I have to pay again to access it?

  • Congress should pass a law requiring any drug producer that received federal money for research to charge no more in the U S than the lowest price they charge outside the U S.

  • My insurance company is making me discontinue a drug, Gabapentin, Horizant to Gabapentin, Gralise due to price. The new drug didn’t work as well as the old one also.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy